KromaTiD, Inc. is a Colorado-based company offering proprietary products and services for the single-cell detection and quantitation of genomic structural variation associated with cellular engineering, genetic diseases, DNA repair, oncology, and other applications.
The Company’s robust and versatile platform, directional Genomic Hybridization (dGH™), provides leading cellular engineering, editing and pharmaceutical companies insight into rearrangements and complex structural variations through direct imaging of DNA structure. The Company’s latest offering, dGH In-Site™, enables direct visualization and measurement of on- and off-target DNA integration events. In-Site captures the genome-wide distribution of small inserts which is not possible with any other method. As the only platform capable of true de novo detection of heterogenous and complex structural rearrangements, KromaTiD’s dGH is an essential and powerful complement to sequencing-based assays. The Company provides research services, as well as probes and kits, and can design and qualify assays for research use and CLIA testing.